Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Per E&P analyst David Nayagam, Sofdra is poised to provide a new treatment option for primary axillary hyperhidrosis, with “a novel and potentially disruptive model for marketing, reimbursement and distribution.” E&P affirms Speculative Buy and $0.55 Price Targe
Euroz Hartleys’ Seth Lizee asserts that “the market opportunity for Sofdra is significant.” Hyperhidrosis is the third largest dermatology condition in the USA with approx. ~10m patients with axillary hyperhidrosis.” Upgraded to Buy and $0.47 Price Target.
Botanix has received firm commitments for $70 million capital raising via an institutional placement. Funds will be applied towards the launch of Sofdra™ (sofpironium) gel, 12.45%, as well as working capital and costs of the placement.
https://botanixpharma.com/wp-content/uploads/Cap-Raise.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-06-21 01:37:462024-06-21 01:37:46Botanix secures commitments for $70 million
Botanix has submitted the last label materials to the US Food & Drug Administration (FDA) for Sofdra™ a pending prescription treatment for excessive underarm sweating. Label discussions are the final step for Botanix before the anticipated FDA approval of Sofdra and have involved product carton design and wording of information that is provided to patients and physicians about the product.
https://botanixpharma.com/wp-content/uploads/Business.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-06-12 00:23:572024-06-12 00:29:46Final Sofdra™ Labelling Discussions with FDA
In new research on Botanix, leading biotech analyst David Nayagam from E&P highlights the “compelling opportunity” that the Company presents and initiates coverage with a speculative buy and $0.55 price target. This increased interest in Botanix comes at a critical time, as we await the commencement of labelling discussions with the FDA – the final regulatory hurdle for Sofdra™ before expected approval in late June 2024.
“Potentially Disruptive” | E&P Analysis
/in Featured, Latest News, News /by Haley ChartresPer E&P analyst David Nayagam, Sofdra is poised to provide a new treatment option for primary axillary hyperhidrosis, with “a novel and potentially disruptive model for marketing, reimbursement and distribution.” E&P affirms Speculative Buy and $0.55 Price Targe
View Report.
Euroz Hartleys Upgrades BOT to Buy
/in Featured, Latest News /by Haley ChartresEuroz Hartleys’ Seth Lizee asserts that “the market opportunity for Sofdra is significant.” Hyperhidrosis is the third largest dermatology condition in the USA with approx. ~10m patients with axillary hyperhidrosis.” Upgraded to Buy and $0.47 Price Target.
View Report.
Botanix secures commitments for $70 million
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix has received firm commitments for $70 million capital raising via an institutional placement. Funds will be applied towards the launch of Sofdra™ (sofpironium) gel, 12.45%, as well as working capital and costs of the placement.
View ASX release.
FDA Approves Sofdra™ topical gel
/in ASX Releases, Featured, Latest News, News /by Haley ChartresFinal Sofdra™ Labelling Discussions with FDA
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix has submitted the last label materials to the US Food & Drug Administration (FDA) for Sofdra™ a pending prescription treatment for excessive underarm sweating. Label discussions are the final step for Botanix before the anticipated FDA approval of Sofdra and have involved product carton design and wording of information that is provided to patients and physicians about the product.
Click here to view ASX release.
“Compelling Opportunity” | E&P Research Report
/in Featured, Latest News, News /by Haley ChartresIn new research on Botanix, leading biotech analyst David Nayagam from E&P highlights the “compelling opportunity” that the Company presents and initiates coverage with a speculative buy and $0.55 price target. This increased interest in Botanix comes at a critical time, as we await the commencement of labelling discussions with the FDA – the final regulatory hurdle for Sofdra™ before expected approval in late June 2024.
View E&P Report.